Honest, research-backed journalism on ivermectin, fenbendazole, HCQ, and your right to medical sovereignty. Updated daily.
Long-term, low-dose azithromycin reduces flare-ups in COPD and bronchiectasis in well-conducted trials—but the benefit carries real trade-offs worth understanding.
Praziquantel kills schistosome blood flukes by forcing calcium into their muscle cells, causing paralysis and exposing them to immune attack—a mechanism decades in the unraveling.
Mebendazole kills intestinal parasites by disrupting microtubules. That same mechanism is why researchers are cautiously studying it in cancer.
Ivermectin is dosed in micrograms per kilogram, not by the pill. Understanding why body weight—not tablet count—determines safety and effect.
Azithromycin lingers in tissues long after blood levels fall, thanks to cellular trapping and immune-cell transport. Here's the real pharmacology behind it.
Streptococcus pneumoniae has developed real, well-documented resistance to azithromycin and related macrolides. Here is what the evidence shows about how and why.
Azithromycin carries a recognized but small risk of heart rhythm changes. Here is what the actual research shows, and who should discuss it with a physician.
Fenbendazole, a decades-old veterinary dewormer, has drawn public attention as a possible cancer treatment. Here is what the research actually establishes—and what it doesn't.
More than a billion people carry intestinal worms picked up from contaminated soil. Here is what the evidence shows about their harm, treatment, and prevention.